Orig3n Closes $12.5M Series A Financing
Orig3n, Inc., a Boston, MA-based biotechnology company developing treatments for rare and genetically inherited diseases, closed a $12.5m Series A financing. The round was co-led by Hatteras Venture Partners and Syno Capital with participation from new investor DEFTA Partners and…